| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia | Sarah de Crescenzo | 08/12/20 | San Francisco |
| Diversity & Inclusion Events Have Halted. Our Conversations Shouldn’t. | Ramsey Johnson | 06/22/20 | Boston |
| Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline | Frank Vinluan | 06/04/20 | Boston |
| Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More | Sarah de Crescenzo | 05/15/20 | National |
| BridgeBio’s Pipeline Expansion Continues as Portfolio’s Milestones Approach | Mandy Jackson | 04/30/20 | San Francisco |
| Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown | Sarah de Crescenzo | 03/23/20 | National |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| BridgeBio Pharma Hauls in $299M for Genetic Disease Drugs R&D | Frank Vinluan | 01/23/19 | San Francisco |
| Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours | Frank Vinluan | 06/21/18 | National |
| Bio Roundup: Not-BIO Party Foul, CRISPR Drama, Sickle Cell Updates | Ben Fidler | 06/15/18 | National |
| Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More | Frank Vinluan | 02/02/18 | National |
| Cullinan Oncology Emerges with $150M to Build Cancer Drug Portfolio | Frank Vinluan | 10/03/17 | Boston |
| Bio Roundup: Phase 3 Fails, Shkreli Jailed, Moderna Flip-Flops & More | Alex Lash | 09/15/17 | National |
| Xconomy Award Finalists in the Eye of the National Drug Price Debate | Alex Lash | 09/13/17 | Boston |
| Bio Roundup: Trumpcare Flails, Spinraza Sales, Batten OK & More | Alex Lash | 04/28/17 | National |
